PODD INSULET CORP


$ 329.03 $ 10.80 (3.39 %)    

Friday, 21-Nov-2025 12:45:59 EST
QQQ $ 591.22 $ 3.88 (0.66 %)
DIA $ 464.27 $ 4.77 (1.04 %)
SPY $ 660.49 $ 5.48 (0.84 %)
TLT $ 89.25 $ -0.41 (-0.46 %)
GLD $ 375.42 $ 1.43 (0.38 %)
$ 312.89
$ 318.62
$ 328.46 x 1
$ 329.91 x 40
$ 318.53 - $ 330.16
$ 230.05 - $ 354.88
1,801,408
na
22.01B
$ 1.07
$ 89.40
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-insulet-raises-price-target-to-380

RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $370 to ...

 btig-maintains-buy-on-insulet-raises-price-target-to-380

BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $370 to $380.

 insulet-announces-20252028-financial-outlook-sees-revenue-projected-to-grow-at-a-cagr-of-20-at-constant-currency-rates-driven-by-continued-omnipod-adoption-and-geographic-expansion-adjusted-operating-margin-expected-to-expand-annually-by-100-basis-points-reflecting-operational-efficiencies-and-growing-scale-adjusted-diluted-eps-anticipated-to-grow-at-a-cagr-of-25-free-cash-flow-forecast-to-remain-strong-enabling-disciplined-reinvestment-in-innovation-and-scaling-globally

Company announces strong long-range financial outlook for 2025–2028Introduces next-generation innovation pipeline to transform ...

 ubs-upgrades-insulet-to-buy-raises-price-target-to-400

UBS analyst Danielle Antalffy upgrades Insulet (NASDAQ:PODD) from Neutral to Buy and raises the price target from $355 to $400.

 btig-reiterates-buy-on-insulet-maintains-370-price-target

BTIG analyst Marie Thibault reiterates Insulet (NASDAQ:PODD) with a Buy and maintains $370 price target.

 canaccord-genuity-maintains-buy-on-insulet-raises-price-target-to-428

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $399 ...

 rbc-capital-maintains-outperform-on-insulet-raises-price-target-to-370

RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $365 to ...

 wells-fargo-maintains-overweight-on-insulet-raises-price-target-to-360

Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Overweight and raises the price target from $3...

 ubs-maintains-neutral-on-insulet-raises-price-target-to-355

UBS analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $320 to $355.

 truist-securities-reiterates-buy-on-insulet-raises-price-target-to-390

Truist Securities analyst Richard Newitter reiterates Insulet (NASDAQ:PODD) with a Buy and raises the price target from $365...

 barclays-maintains-equal-weight-on-insulet-raises-price-target-to-316

Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $301 to $316.

 jefferies-maintains-buy-on-insulet-raises-price-target-to-400

Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $375 to $400.

 insulet-sees-q4-sales-746875m-764800m-vs-728218m-est

2025 Outlook:For the quarter and year ending December 31, 2025, the Company is providing the following guidance (revenue in con...

 insulet-raises-fy2025-sales-guidance-from-2569b-2631b-to-2652b-2672b-vs-2626b-est

2025 Outlook:For the quarter and year ending December 31, 2025, the Company is providing the following guidance (revenue in con...

 insulet-q3-adj-eps-124-beats-114-estimate-sales-706300m-beat-676726m-estimate

Insulet (NASDAQ:PODD) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.14 by 8.96...

 barclays-maintains-equal-weight-on-insulet-raises-price-target-to-301

Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $300 to $301.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION